| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 05/23/2000 | US6066730 Boronic ester and acid compounds, synthesis and uses |
| 05/23/2000 | US6066722 Nucleoside analogues used as antiprotozoal agents especially against plasmodium |
| 05/23/2000 | US6066719 Immunoglobulin heavy chain fragment associated with two light chains which each comprise a variable domain and form two functional antigen binding positions; for use in isolation of antibodies |
| 05/23/2000 | US6066718 Culturing host encoding dna capable of expressing antibody against immunoglobulin e, isolating, and conjugating with an enzyme, a fluorescent or chemiluminescent marker, a cytotoxic or cytostatic substance, radioactive label or others |
| 05/23/2000 | US6066662 Use in control or prevention of rheumatoid arthritis and osteoarthritis or in the treatment of invasive tumours, atherosclerosis or multiple sclerosis |
| 05/23/2000 | US6066657 For the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting tumor necrosis factor or phosphodiesterase iv |
| 05/23/2000 | US6066641 Phosphodiesterases as molecular targets for anti-asthmatic agents |
| 05/23/2000 | US6066498 Compositions for the treatment and diagnosis of immune disorders |
| 05/23/2000 | US6066322 Administering antibody to treat asthma; treating helper t-cell mediated conditions |
| 05/23/2000 | US6066321 Diagnosing inflammation and autoimmune diseases |
| 05/23/2000 | US6066317 Method of using IL-11 for treating deficiencies in hematopoietic progenitor or stem cells |
| 05/23/2000 | CA2171637C Substituted azaheterocyclecarboxylic acids |
| 05/18/2000 | WO2000028048A1 Novel plasmids for use in medicine and method of producing same |
| 05/18/2000 | WO2000028045A2 Human hydrolase proteins |
| 05/18/2000 | WO2000028035A1 CHEMOKINE β-7 |
| 05/18/2000 | WO2000028019A2 Antisense oligomer |
| 05/18/2000 | WO2000028010A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 05/18/2000 | WO2000028001A1 Modified exosomes and uses |
| 05/18/2000 | WO2000027999A2 Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices |
| 05/18/2000 | WO2000027881A2 Human interleukin 10 mutant proteins |
| 05/18/2000 | WO2000027880A2 Rantes-derived peptides with anti-hiv activity |
| 05/18/2000 | WO2000027870A1 Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof |
| 05/18/2000 | WO2000027850A2 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | WO2000027845A1 Spiro-indolines as y5 receptor antagonists |
| 05/18/2000 | WO2000027822A2 Tricyclic pyrazole derivatives |
| 05/18/2000 | WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 05/18/2000 | WO2000027802A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 05/18/2000 | WO2000027792A1 Novel compounds and medicinal use thereof |
| 05/18/2000 | WO2000027433A1 Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants |
| 05/18/2000 | WO2000027432A1 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS |
| 05/18/2000 | WO2000027421A2 LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE |
| 05/18/2000 | WO2000027414A2 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | WO2000027402A1 Remedies for topical administration for iv type allergic diseases |
| 05/18/2000 | WO2000027392A1 Chromone enteric release formulation |
| 05/18/2000 | WO2000027373A1 Dry powder pharmaceutical formulation |
| 05/18/2000 | WO2000027363A1 Aerosols comprising nanoparticle drugs |
| 05/18/2000 | WO2000027359A1 An inhalation system |
| 05/18/2000 | WO2000027207A1 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof |
| 05/18/2000 | WO2000027205A1 A recombinant polypeptide for use in the manufacture of vaccines against campylobacter induced diarrhea and to reduce colonization |
| 05/18/2000 | WO2000009734A3 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 05/18/2000 | WO2000009479A3 Heterocyclic thioesters or ketones for vision and memory disorders |
| 05/18/2000 | WO2000008202A3 3-methylidenyl-2-indolinone modulators of protein kinase |
| 05/18/2000 | WO1999058096A3 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| 05/18/2000 | DE19945814A1 Verfahren zur Zubereitung eines pharmazeutischen Artemisia-Extraktes und Vorrichtung zur elektrischen Moxibustion unter Verwendung des Extraktes A process for the preparation of a pharmaceutical Artemisia extract and moxibustion device for electrically using the extract |
| 05/18/2000 | DE19848260A1 Fumarsäure-Mikrotabletten Fumaric microtablets |
| 05/18/2000 | CA2351889A1 Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices |
| 05/18/2000 | CA2351063A1 A system for administering a bioactive agent by inhalation comprising a lipid mixture comprising phosphatidylcholine |
| 05/18/2000 | CA2350771A1 Chemokine .beta.-7 |
| 05/18/2000 | CA2350714A1 Spiro-indolines as y5 receptor antagonists |
| 05/18/2000 | CA2350388A1 Human hydrolase proteins |
| 05/18/2000 | CA2350235A1 Tricyclic pyrazole derivatives |
| 05/18/2000 | CA2350183A1 Use of an enterobacterium protein ompa for specific targeting towards antigen-presenting cells |
| 05/18/2000 | CA2349904A1 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | CA2349679A1 Modified exosomes and uses |
| 05/18/2000 | CA2349445A1 Antisense oligomer |
| 05/18/2000 | CA2348763A1 Novel compounds and medicinal use thereof |
| 05/18/2000 | CA2348308A1 Rantes-derived peptides with anti-hiv activity |
| 05/18/2000 | CA2347916A1 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | CA2345459A1 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 05/17/2000 | EP1001032A2 Recombinant retroviruses delivering vector constructs to target cells |
| 05/17/2000 | EP1000930A2 Tachykinin antagonists |
| 05/17/2000 | EP1000628A1 Use of antigenic complexes of HIV envelope and HLA class I antigens as HIV vaccine |
| 05/17/2000 | EP1000626A1 Chemokine receptor antagonist and cyclosporin in combined therapy |
| 05/17/2000 | EP1000163A1 $i(PSEUDOMONAS) EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS |
| 05/17/2000 | EP1000161A1 Anticoagulant fusion protein anchored to cell membrane |
| 05/17/2000 | EP1000158A1 Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders |
| 05/17/2000 | EP1000084A1 123 human secreted proteins |
| 05/17/2000 | EP1000060A1 Novel compounds |
| 05/17/2000 | EP1000055A1 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| 05/17/2000 | EP1000051A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/17/2000 | EP1000040A1 Il-5 inhibiting 6-azauracil derivatives |
| 05/17/2000 | EP1000035A1 Substituted 6-phenylphenanthridines |
| 05/17/2000 | EP1000034A1 Substituted 6-alkylphenanthridines |
| 05/17/2000 | EP1000031A1 Vitronectin receptor antagonist |
| 05/17/2000 | EP1000017A1 Il-8 receptor antagonists |
| 05/17/2000 | EP0999853A1 Stabilized antibody formulation |
| 05/17/2000 | EP0999852A1 Oil in water vaccine compositions |
| 05/17/2000 | EP0999846A1 Phosphatidic acid-based immune modulator composition |
| 05/17/2000 | EP0999842A1 Novel substituted imidazole compounds |
| 05/17/2000 | EP0999838A1 Self-emulsifying formulation for lipophilic compounds |
| 05/17/2000 | EP0999826A1 Self-emulsifying formulation for lipophilic compounds |
| 05/17/2000 | EP0726768B1 Use of nitric oxide releasing compounds for the manufacture of a medicament for protection in ischemia reperfusion injury |
| 05/17/2000 | EP0605700B1 Flavopereirine-based pharmaceutical composition and use thereof for treating hiv |
| 05/17/2000 | CN1253589A Human complement C3-degrading proteinase from streptococcus pneumoniae |
| 05/17/2000 | CN1253567A Cell surface molecule mediating cell adhesion and signal transmission |
| 05/17/2000 | CN1253565A Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines |
| 05/17/2000 | CN1253561A Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5) for treatment of sexual dysfunction |
| 05/17/2000 | CN1253560A Sulfonamides for treatment of endothelin-mediated disorders |
| 05/17/2000 | CN1253557A Vitamin D3 analogs with bis C-20 side chains |
| 05/17/2000 | CN1253553A Substituted phenyl derivatives, their preparation and use |
| 05/17/2000 | CN1253549A Benzimidazole derivative |
| 05/17/2000 | CN1253545A Aryl sulfonamides and analogues thereof and their use in treatment of neurodegenerative diseases |
| 05/17/2000 | CN1253504A Cytokine related treatments of disease |
| 05/17/2000 | CN1253499A Drug composition |
| 05/17/2000 | CN1253176A Composition and method for protecting animals from diseases related with slow action virus |
| 05/17/2000 | CN1052510C Mammalian receptors for interleukin-10 |
| 05/16/2000 | US6063900 Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof |
| 05/16/2000 | US6063797 γ-RAR antagonist ligand or α-RAR agonist ligand as an apoptosis inhibitor |
| 05/16/2000 | US6063762 Cyclosporin microemulsion with oils, solvents and surfactants |
| 05/16/2000 | US6063621 Hybridoma cell qcrl-1 having atcc accession number hb 11765; for production of monoclonal antibodies for use as antitumor agents and diagnostic reagents |